Skip NavigationSkip to Content
Return Return to Search Results

Kikwit Ebola Virus Disease Progression in the Rhesus Monkey Animal Model

  1. Author:
    Bennett, Richard S [ORCID]
    Logue, James [ORCID]
    Liu, David X
    Reeder, Rebecca J
    Janosko, Krisztina B
    Perry, Donna L
    Cooper, Timothy K
    Byrum, Russell
    Ragland, Danny
    St Claire, Marisa
    Adams, Ricky [ORCID]
    Burdette, Tracey L
    Brady, Tyler M
    Hadley, Kyra
    Waters, M Colin
    Shim, Rebecca
    Dowling, William
    Qin, Jing
    Crozier,Ian
    Jahrling, Peter B
    Hensley, Lisa E

  2. Author Address

    Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA., Research Resources Section, Office of Biodefense, Research Resources, and Translational Research/Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892-9825, USA., Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, USA., Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702 USA., Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 21702, USA.,
    1. Year: 2020
    2. Date: Jul 14
    3. Epub Date: 2020 07 14
  2. Journal: VIRUSES-BASEL
    1. 12
    2. 7
    3. Pages: E753
  4. Type of Article: Article
  5. Article Number: 753
  6. ISSN: 1999-4915
  1. Abstract:

    Ongoing Ebola virus disease outbreaks in the Democratic Republic of the Congo follow the largest recorded outbreak in Western Africa (2013-2016). To combat outbreaks, testing of medical countermeasures (therapeutics or vaccines) requires a well-defined, reproducible, animal model. Here we present Ebola virus disease kinetics in 24 Chinese-origin rhesus monkeys exposed intramuscularly to a highly characterized, commercially available Kikwit Ebola virus Filovirus Animal Non-Clinical Group (FANG) stock. Until reaching predetermined clinical disease endpoint criteria, six animals underwent anesthesia for repeated clinical sampling and were compared to six that did not. Groups of three animals were euthanized and necropsied on days 3, 4, 5, and 6 post-exposure, respectively. In addition, three uninfected animals served as controls. Here, we present detailed characterization of clinical and laboratory disease kinetics and complete blood counts, serum chemistries, Ebola virus titers, and disease kinetics for future medical countermeasure (MCM) study design and control data. We measured no statistical difference in hematology, chemistry values, or time to clinical endpoint in animals that were anesthetized for clinical sampling during the acute disease compared to those that were not.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/v12070753
  3. PMID: 32674252
  4. View record in Web of Science®
  5. WOS: 000557075700001
  6. PII : v12070753

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel